Evolving role of VIADISC for chronic low back and discogenic pain : a narrative review
INTRODUCTION: Chronic lower back pain is a leading cause of disability and healthcare spending worldwide. Discogenic pain, pain originating from the intervertebral disk, is a common etiology of chronic lower back pain. Currently, accepted treatments for chronic discogenic pain focus only on the management of symptoms, such as pain. There are no approved treatments that stop or reverse degenerating intervertebral discs. Biologic therapies promoting disc regeneration have been developed to expand treatment options. VIADISC™ NP, is a viable disc allograft supplementation that, in a recent trial, demonstrated a significant reduction in pain and increased function in patients suffering from symptomatic degenerative disc disease.
AREAS COVERED: This manuscript summarizes the epidemiology and etiology of low back pain, the pathophysiology of degenerative disc disease, current treatments, and a need for newer therapies. The rationale behind intradiscal biologics for the treatment of symptomatic degenerative disc disease is also discussed.
EXPERT OPINION: Characterization of the biology leading to disc degeneration has allowed for the development of intradiscal biologics. They may soon be capable of preventing and reversing disc degeneration. Clinical trials have shown promise, but further research into efficacy and safety is needed before these therapies are widely employed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Expert opinion on emerging drugs - (2024) vom: 15. Apr., Seite 1-10 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tolson, Jack K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Allograft |
|---|
| Anmerkungen: |
Date Revised 15.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/14728214.2024.2339912 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370914740 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370914740 | ||
| 003 | DE-627 | ||
| 005 | 20240415233739.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240411s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14728214.2024.2339912 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1376.xml |
| 035 | |a (DE-627)NLM370914740 | ||
| 035 | |a (NLM)38602142 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tolson, Jack K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evolving role of VIADISC for chronic low back and discogenic pain |b a narrative review |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a INTRODUCTION: Chronic lower back pain is a leading cause of disability and healthcare spending worldwide. Discogenic pain, pain originating from the intervertebral disk, is a common etiology of chronic lower back pain. Currently, accepted treatments for chronic discogenic pain focus only on the management of symptoms, such as pain. There are no approved treatments that stop or reverse degenerating intervertebral discs. Biologic therapies promoting disc regeneration have been developed to expand treatment options. VIADISC™ NP, is a viable disc allograft supplementation that, in a recent trial, demonstrated a significant reduction in pain and increased function in patients suffering from symptomatic degenerative disc disease | ||
| 520 | |a AREAS COVERED: This manuscript summarizes the epidemiology and etiology of low back pain, the pathophysiology of degenerative disc disease, current treatments, and a need for newer therapies. The rationale behind intradiscal biologics for the treatment of symptomatic degenerative disc disease is also discussed | ||
| 520 | |a EXPERT OPINION: Characterization of the biology leading to disc degeneration has allowed for the development of intradiscal biologics. They may soon be capable of preventing and reversing disc degeneration. Clinical trials have shown promise, but further research into efficacy and safety is needed before these therapies are widely employed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Allograft | |
| 650 | 4 | |a biological therapy | |
| 650 | 4 | |a degenerative disc disease | |
| 650 | 4 | |a discogenic pain | |
| 650 | 4 | |a intervertebral disc | |
| 650 | 4 | |a lower back pain | |
| 650 | 4 | |a nucleus pulposus | |
| 700 | 1 | |a Menuet, Robert L |e verfasserin |4 aut | |
| 700 | 1 | |a Ly, Gianni H |e verfasserin |4 aut | |
| 700 | 1 | |a Chanes, Benjamin A |e verfasserin |4 aut | |
| 700 | 1 | |a Bryan, Elizabeth A |e verfasserin |4 aut | |
| 700 | 1 | |a Kataria, Saurabh |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Julian |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmadzadeh, Shahab |e verfasserin |4 aut | |
| 700 | 1 | |a Shekoohi, Sahar |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Alan D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on emerging drugs |d 2001 |g (2024) vom: 15. Apr., Seite 1-10 |w (DE-627)NLM143290835 |x 1744-7623 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:15 |g month:04 |g pages:1-10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14728214.2024.2339912 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 15 |c 04 |h 1-10 | ||